ArticleTransactions of the American Clinical and Climatological Association2004
Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice.
Article in Transactions of the American Clinical and Climatological Association, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).International journal of oncology · 2024Pooled it
- Article
- Membrane-Fusing Vehicles for Re-Sensitizing Transporter-Mediated Multiple-Drug Resistance in Cancer.Pharmaceutics · 2024Article
- Computational Drug Repositioning Identifies Potentially Active Therapies for Chordoma.Neurosurgery · 2021Article
- Inhaled chemotherapy adverse effects: mechanisms and protection methods.Lung cancer management · 2020Review
- Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPacJournal of aerosol medicine and pulmonary drug delivery · 2019Article
- Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.International journal of molecular sciences · 2012Review
- Inhaled chemotherapy in lung cancer: future concept of nanomedicine.International journal of nanomedicine · 2012Review
- Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer.Molecular cancer therapeutics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel (PTX) is a lipophilic agent with broad anticancer activity. In the present study we examined the antitumor effect and toxicity of co-administration of cyclosporine A (CsA) and PTX in liposomal aerosol using the Renca lung metastases mouse model. The untreated and PTX-only groups exhibited cancer growth while CsA aerosol plus PTX had more favorable effects on tumor growth. Weight loss was seen in mice treated with CsA/PTX+CsA by day 9 to 22. Histopathological examination showed no toxicity following treatment. The findings offer evidence that a combination of CsA and PTX may be suitable for aerosol treatment of lung cancer if it is possible to control toxicity of the therapy.
Indexed as
Identifiers
17060982PMC2263789W3021321599What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.